Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

En-CPhI.CNOctober 17, 2019

Tag: Hepagene , HPG1860 , NASH

PharmaSources Customer Service